PRENOSIMO VIJESTI MPN RESEARCH FOUNDATION ZA SRPANJ 2022.

Prenosimo brojne vijesti MPN istraživačke fondacije.
 
Izvor: MPN RF
 
 
2022
Hiking for MPN Awareness … and a cure
On August 3rd, a team of MPN patients, caregivers and advocates will begin a challenging five-day endurance adventure as part of Sole 2 Soul for MPN. This program is an innovative collaboration of the MPN Research Foundation, CURE Media Group, and the Canadian MPN Research Foundation. The goal is to challenge the inner adventurer while raising funds to fuel change for those who face MPNs. Join us in rooting on our MPNRF team and helping them meet their fundraising goal. Learn more here.
Thrive Initiative Funding Deadline Approaching
 
The Thrive Initiative focuses on research funding gaps, including from pandemic impacts on the research community. The overall goal is to continue contributing to the scientific understanding of MPNs and how it can lead to better outcomes and eventual cures for MPN patients. 
 
MPNRF gratefully acknowledges the Leukemia & Lymphoma Society for its generous funding contributions toward this initiative. Learn more and apply here.
“We are proud of our long-standing relationship with the MPN Research Foundation to fund research towards more effective and safer treatments for MPN. Our organizations are driving the groundbreaking research that is helping people with MPN live a better quality of life.”
– Lee Greenberger, LLS Chief Scientific Officer  
Patient Centered MPN Care
Patient Empowerment Network hosts a
30-minute webinar August 9th at 1pm EDT on how to access the best possible care for MPNs. With so many exciting developments in the research pipeline, there are many questions for patients and their loved ones. Are there alternate treatment strategies for MPN patients who have failed all therapies? Should I consider a clinical trial as a path to enhancing my care? Join internationally recognized MPN expert Dr. Claire Harrison for this moderated discussion around achieving patient-centered MPN care. Register here
 
Registration Still Open: Texas MPN Workshop
 
  
Mays Cancer Center, home to UT Health San Antonio MD Anderson, hosts the 2022 Texas MPN Workshop, August 26-27. This third annual meeting on MPNs is a hybrid event, with attendance in person or virtually. International MPN thought leaders and key investigators will gather to discuss new research and the many new therapy options in development for people living with MPNs, including a deep dive into the role of current and new therapies. MPNRF is hosting a session titled, “MPN Disease from Pathogenesis to Progression.” See details and register here: Texas MPN Workshop 
Make a Gift. Make an Impact.
Research into MPNs is not quick or easy, or without considerable expense. While funding today’s research supports our current progress, the level of research investment over the coming decades must be increased in order to find answers, new treatments, and potentially a cure for essential thrombocythemia, polycythemia vera and myelofibrosis. As you consider what’s important to you, we encourage you to think about making a future gift to MPN Research Foundation through your estate. In this way, you can stamp your legacy on the future of MPN research.
 
To learn more, explore our website at  Planned Giving | MPN Research Foundation. To speak with someone directly, contact our Development Office at (312) 683-7249 or giving@mpnrf.org
 
Spreading the Facts:
September is Blood Cancer Awareness Month
Watch for MPN Research Foundation’s 30 FACTS ABOUT MPN. This 30-day social media campaign will run throughout September, with a focus on the importance of clinical trials, what patients should know, and how researchers and practitioners can make an even greater impact on people living with an MPN. Follow us on Facebook, Instagram, Twitter and Linkedin so you can share the posts to help increase MPN awareness! 
 
Clinical Trial Highlights
 
Ruxolitinib  
Sponsor: Massachusetts General Hospital  
 
Phase 2 trial for low-risk PV or ET patients able to travel to trial sites in Massachusetts to determine if ruxolitinib is effective in symptom reduction. 
  
DISC-0974 
Company: Disc Medicine, Inc.   
 
Phase 1/2 trial for MF patients with anemia. Study drug is a monoclonal antibody developed to target hemojuvelin, a key regulator of hepcidin and iron homeostasis, to increase circulating iron availability.  
 
The MPN Research Foundation clinical trial finder – powered by Trialjectory – easily and quickly matches an MPN patient’s diagnosis and medical history. By filling out a short profile, a list is generated that a patient can share with a doctor who manages their MPN. And live support is available in multiple languages. Get started here today.
Our mission is supported by the generosity of our donors and sponsors.
 
180 N. Michigan Avenue, Suite 1870 | Chicago, IL 60601
 
 

Podijeli

Zagreb, HR
20°C
vedro

Hrvatska udruga leukemija i limfomi
predsjednik Dražen Vincek
Trg hrvatskih velikana 2/ll
10 000 Zagreb
OIB:51774844072
MB: 01136763
REG. BR.: 00000797
GSM: +385 (0)91 4873 561
TEL: +385 (0)1 4873 561
e-mail: udruga.hull.zagreb@gmail.com
Web adresa: www.hull.hr
IBAN: HR 36 2340 0091 1100 4711 4
SWIFT CODE: PBZGHR2X

Važni datumi

Health through Knowledge

Klasa optimist

Igor Delač- Samo zbog vas

(Ivan Zečić/Miroslav Zečić – Miroslav Zečić/Ivan Zečić) ℗ 2021 Croatia Records

Istaknuti sponzori HULL-a